Tenax Therapeutics is trading at $1.50, up 10.29%; a broader rebound in technology stocks and Nasdaq futures may be a market-sentiment factor. - No verified company-specific announcement was found for October 19. - The backdrop remains challenging: the Phase 3 LEVEL trial missed its primary and key secondary endpoints, though a more severe-disease subgroup showed benefit. The trial news was reported October 18, but available sources do not establish it as the cause of this morning’s gain.